Reassessing the role of axillary lymph-node dissection in patients with early-stage breast cancer

Canadian Journal of Surgery

Volumn 46, Issue 4, 2003, Pages 285-289

  Marschall, Jeff ^a,b   Nechala, Patrik ^a   Colquhoun, Patrick ^a   Chibbar, Rajni ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b Box 7777 ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MEDICAL SOCIETY; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODE EXCISION; MASTECTOMY, SEGMENTAL; PROGNOSIS;

EID: 0042035639     PISSN: 0008428X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. The Steering Committee on clinical practice guidelines for the care and treatment of breast cancer. Axillary dissection. CMAJ 1998;158(3 Suppl):S22-6.
2. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer. A review. Cancer 1995;76:1491-512.
3. Goldhirsch A, Glick JH, Gelber RD, Senn H. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998;90: 1601-8.
4. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer [see comments]. N Engl J Med 2002;347: 1233-41. Comments in: N Engl J Med 2002;347:1270-1; N Engl J Med 2003;348:657-60, author reply 657-60.
5. Chetty U, Jack W, Prescott RJ, Tyler C, Rodger A. Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial. Br J Surg 2000;87:163-9.
6. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival - a Bayesian meta-analysis. Ann Surg Oncol 1999;6:109-19.
7. Parmigiani G, Berry DA, Winer EP, Tebladi C, Iglehart DJ, Prosnitz LR. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol 1999;17:1465-73.
8. Dees EC, Shulman LN, Souba WW, Smith BL. Does information from axillary dissection change treatment in clinically nodenegative patients with breast cancer? An algorithm for assessment of impact of axillary dissection. Ann Surg 1997;226:279-86.
9. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for Tla breast carcinoma: Is it indicated? Cancer 1994;73:664-7.
10. Haffy BG, Ward B, Pathare P, Salem R, McKahn C, Beinfield M, et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 1997;15:691-700.
11. The Ludwig Breast Group. Prolonged disease-free survival after one course of postoperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989;320:491-6.
12. Ivens D, Hoe A, Podd T, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992;66:136-8.
13. Roses DF, Brooks AD, Harris MN, Shapiro RL, Mitnick J. Complications of level I and II axillary dissection in the treatment of carcinoma of the breast. Ann Surg 1999;230:194-201.
14. Keshtgar MR, Baum M. Axillary dissection over the years: Where to from here? World J Surg 2001;25:761-6.
15. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 2001;30:5-15.
16. Aapro MS. Adjuvant therapy of primary breast cancer: a review of key findings of the 7th international conference, St. Gallen, February 2001. Oncologist 2001;6:376-85.
17. Morris A, Morris R, Wilson J, White J, Steinberg S, Okunieff P, et al. Breast conserving therapy vs mastectomy in early stage breast cancer: a meta-analysis of ten years survival. Cancer J 1997;3:6-12.
18. Greco M, Gennaro M, Valagussa P, Agresti R, Ferraris C, Ferrari B, et al. Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. Istituto Nazionale per lo Studio e las Cura dei Tumori. Ann Oncol 2000;11:1137-40.
19. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
20. Bass SB, Cox CE, Ku NN, Berman C, Reintgen DS. The role of sentinel lymph node biopsy in breast cancer. J Am Coll Surg 1999;189:183-94.
21. Cabanes PA, Salmon RJ, Vilcoq JR, Durand JC, Fourquet A, Gautier C, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie. Lancet 1992;339:1245-8.
22. Jatoi I. Management of the axilla in primary breast cancer. Surg Clin North Am 1999;79:1061-73.
23. Singletary SE. Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer. Am J Surg 2001;182:341-6.
24. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999;230:72-8.
25. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomized controlled trials with quality adjusted survival analysis. Lancet 2001;358:277-86.
26. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Adjuvant systemic therapy for women with node-negative breast cancer. CMAJ 1998;158(3 Suppl): S43-51.
27. Galper SR, Lee SJ, Tao ML, Troyan S, Kaelin CM, Harris JR, et al. Patient preference for axillary dissection in the management of early-stage breast cancer. J Natl Cancer Inst 2000;92:1681-7.